Ailux Biologics
June 16, 2025
Company Presentation
Platform for Therapeutics
Ailux Biologics is the biologics division of XtalPi (“XtalPi Holdings Limited”, stock code: 2228.HK), a global leader in AI-driven drug discovery. At Ailux, we are dedicated to developing differentiated complex biologics with a practical mindset. Our tool-agnostic approach integrates cutting-edge AI platforms with robust wet-lab capabilities and expert-driven insights—enabling the design and development of better biologics, faster and smarter.
Company HQ City:
Somerville
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
Ailux Biologics: 2023
XtalPi: 2014
Lead Product in Development:
SIGX1094 for the treatment of diffuse gastric cancer (DGC) and other advanced solid tumors (partnership between XtalPi and Signet Therapeutics)
CEO
Yi Li, Head of Ailux Biologics, Vice President of XtalPi
Ma Jian, Co-founder and CEO of XtalPi
Development Phase of Lead Product
Phase I
Exchange
HKSE
Ticker
2228.HK
When you expect your next catalyst update?
Drug discovery partnership between major pharma and Ailux Biologics
What is your next catalyst (value inflection) update?
H2 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}